It is challenging for CKD patients to stay on spironolactone therapy because it can increase the risk of hyperkalemia, according to researchers.
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.
In a large study of patients with chronic kidney disease, metabolic acidosis independently increased the risk of progressing to end-stage renal disease and death.
In a study, upper arm arteriovenous fistulas were associated with better hemodialysis access survival.
The interdependence of trajectories in patient parameters, such as albumin and white blood cell count, may suggest certain disease processes.
Patients with Staphylococcus aureus catheter-related bloodstream infections are the most likely to present with fever, rigor, or both, a study found.
Hemodialysis patients who stayed on the phosphate binder sucroferric oxyhydroxide for 2 years had fewer hospitalizations those who switched to another binder for 2 years.
Prescription patterns suggest patiromer is used more often for chronic treatment of hyperkalemia and polystyrene sulfonate for episodic treatment.
In a study of hemodialysis patients, only 0.6%, 0.5%, and 0.9% hypokalemia events occurred at 1, 2, and 3 months after initiating patiromer treatment.
In type 2 diabetes patients, a dementia diagnosis preceded vascular events such as kidney disease progression by a mean 2998 days or roughly 8 years.
Patients receiving hemodialysis with arteriovenous fistulas vs central venous catheters are less likely to die or be hospitalized.
In a small study of hemodialysis patients, the highest 3 quartiles of serum thyrotropin were associated with nearly triple the risks for worse endothelial function.
From 1999 to 2018, the proportion of living kidney donors classified as overweight or mildly obese increased, while the proportion of those considered moderately or morbidly obese has decreased, a study found.
Even a low HAS-BLED score of 0 was associated with high risk for bleeding in this population: 5.6 per 100 patient-years.
Nearly half of patients with autosomal dominant polycystic kidney disease receive at least 1 CT scan over 2 years, study finds.